Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQB: ATTBF) (CSE: ATT), is a specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets, some of which will contain cannabinoid compounds. Abattis develops and is in the process of commercializing natural health products that target ailments and satisfy important market needs. Abattis is conducting ongoing research and development to create plant-based intellectual property and ingredients. Current areas of focus are growth through acquisition and business development and cash flow through commercialization of existing assets.
Through our divisions Biocell Labs Inc. and Vergence Sales & Marketing Group, we develop and license natural health products and have future plans to expand into the nutraceutical, pharmaceutical and cosmetic markets. The Company has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding natural health product market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions.
Within our other divisions Northern Vine, North American Bioextracts and Biocube we have capabilities that support the production and extraction of botanical ingredients for our products; one of which includes cannabis.
Northern Vine LaboratoriesTM (Northern Vine LabsTM) seeks to become the premier analytical testing laboratory, and research and development partner to the legal cannabis industry in Canada - Executive Overview
For more information, visit the Company's website at: www.abattis.com.
Our investors are forward thinkers in the emerging bioceutical and medical marijuana markets. We are a specialty, vertically-integrated biotechnology company that aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. From patented and proprietary formulations, extraction and processing methods, Abattis consistently seeks opportunities to participate in varied markets all connected by a common global purpose and customer base: seeking health through natural products. Abattis is uniquely positioned to fully exploit the growing trend toward marijuana legalization in the United States and medicinal use in Canada as licensed and international jurisdictions.
“Health Canada estimates that the emerging medical marijuana market to be in excess of $1 billion.
Stephen Easton, an SFU Economist, estimated that nationally the Cannabis industry generates approximately $19 to $21 billion”
We develop and license natural health products with unique botanical blends, CBD and proprietary ingredients. These infused food and beverage brands are designed for wellness nutraceuticals, medical foods & botanical drugs market with future plans to expand into the pharmaceutical and cosmetic markets.
Canada’s cannabis industry is expected to surpass $22 billion in size over the coming years, according to Deloitte, with over 140,000 registered medical marijuana patients today. With about 40 licensed producers under the ACMPR, the industry is expected to see a shortfall in supply given the 205% compound annual growth rate in registered patients since June of 2014 along with the near-term plans to legalize marijuana for recreational use.
As an investor, you are our partner and we take this relationship seriously. Please contact us if you have any questions or if you would like to invest in Abattis.
Goldman Small Cap Research report, 'This Stock Set to Double Thanks to New License'
Abattis Bioceuticals Corp. - Stock Up Big on Recent News, Greater Gains on Horizon (October 20, 2016).
Goldman Small Cap Research report 'The Next Industry-Changing Specialty Health Stock'
Abattis Bioceuticals Corp. - Major Revenue Ahead for Innovative, Diversified Bioceuticals Pioneer (June 13, 2016).
Northern Vine Labs™ is getting ready for our launch.
Visit our website and join our community for updates and educational information.
#knowyourbud #abattis #northernvinelabs
Northern Vine Labs™ are now on Health Canada list for licensed dealers!
The table below contains a list of laboratories that have a current Dealers Licence under the Narcotic Control Regulations and who are licensed to conduct activities with cannabis: 
Northern Vine Labs™, a subsidiary of Abattis, seeks to become the premier analytical testing laboratory, and research and development partner to the legal cannabis industry in Canada. The ability to legally work with Cannabis remains rare and highly specialized. Northern Vine Labs™ Controlled Substance License enables proprietary methods and services to be offered to currentlicensed producers within Canada’s existing Federal regulatory structure. It also offers Northern Vine Labs™ customers, including Abattis, the ability to formulate and develop new products containing cannabinoid ingredients in advance of the end to prohibition.
In partnership with the BC Institute of Technology (BCIT), Northern Vine Labs™ has been working to develop new and improved methods for the analysis of cannabis. This work is expected to be published by BCIT positioning NV Labs as the industry expert in analytical services which are substantially faster and more reliable than any other in Canada. Utilizing these proprietary methods, Northern Vine Labs will offer for sale its analytical reference standards enabling market participants to check quality and metrological traceability of products, to validate analytical measurement methods, and/or to support the proper calibration of instruments. Northern Vine Labs™ operations under the CSL will include:
1. Analytical Services
2. Research and Development Services
3. Extraction to Support Analysis and R&D?
In future, NV Labs anticipates the opportunity to amend its license to include:
4. Extraction service for sale of extracted ingredients
5. Importation/Exportation
Analytical Services
Potency Testing Determining composition and concentration of various cannabinoid compounds
Moisture Analysis and Foreign Matter Testing
Microbiological Testing
Ensuring the safety of products by testing for levels of mold and bacteria.
The Cannabis Trade Alliance of Canada, which represents producers, said the new regime should provide for mandatory testing:
“Mandatory laboratory testing of all cannabis products (potency and contaminants) – a critical step in the seed-to-sale process when considering public health, and should be the main objective in the legalized framework.”
Report of the Task Force on Cannabis Legalization and Regulation 
Vergence Visionary Bioceuticals, a subsidiary of Abattis, is a team of nutraceutical marketing and brand specialists focused on innovative health products to penetrate the fast growing market for natural, safe and effective solutions to two of society’s unresolved and ubiquitous health issues: Pain caused by inflammation and mental ailments common to our modern lifestyle. Vergence is the exclusive exporter of 99.6%, organic and pure CBD Isolate out of Hong Kong and directly to the rest of the world. Together with a vast distribution network and custom product and branded formulations via Northern Vine Labs, Vergence aims to promote healthy living through natural remedies. Vergence is in possession of over 100 Natural Product Numbers (NPN's) as granted by Health Canada and plans to develop and distribute these products into global markets for end use.
Abattis Bioceuticals Corporation
Address: 104 - 9295 198th Street | Langley, BC V1M 3J9 | Canada
Phone: 778-883-7869 (Corporate Communications: Brook Bellian)
Email: news@abattis.com
Website: http://www.abattis.com
Abattis Bioceuticals
Phone: (604) 336.0881
Northern Vine
Phone: (604) 336.0881 | (604) 371.3371 | (604) 888.1129
CHINA | Dr. Shuang Xie Ph. D.
Suzhou Raybot Material Tech Ltd
T: 17785884380 | C: 17783175968
Phone: 86 5125240581 | 8613901388668
Address: No. 10-1 Yang Yuan Road,
Xinzhuang Zhen,Changshu | China
OUTSTANDING COMMON SHARE DATA
There are an unlimited number of common shares without par value authorized for issue. At September 30, 2016, there were 111,760,004 issued and fully paid common shares and 1,750,000 common shares in treasury.
Issued & Outstanding (07/01/2017): The Company has 159,656,060 common shares issued and outstanding (source)